Status:
COMPLETED
eRAPID: Online Symptom Reporting in Lung Cancer
Lead Sponsor:
University of Leeds
Collaborating Sponsors:
The Leeds Teaching Hospitals NHS Trust
Iqvia Pty Ltd
Conditions:
Thoracic Cancer
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Lung cancer is a leading cause of cancer-related ill-health and death in the United Kingdom (UK), but with advances in systemic anti-cancer therapies the prognosis for people in later stages is improv...
Detailed Description
Background: Lung cancer is a leading cause of cancer-related morbidity and mortality. There are 2 main categories of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). ...
Eligibility Criteria
Inclusion
- Diagnosis of thoracic cancer: Non-small cell lung cancer (NSCLC), or Small cell lung cancer (SCLC), or Pleural mesothelioma
- Start of a systemic anti-cancer therapy with prescribed chemotherapy, tyrosine kinase inhibitors (TKIs) or checkpoint inhibitors within the recruitment period
- Willing and able to provide written informed consent
- Fluency in English
Exclusion
- Cognitive impairment
- Receiving best-supportive care only
Key Trial Info
Start Date :
July 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT04324437
Start Date
July 20 2020
End Date
December 31 2023
Last Update
May 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St James's University Hospital, Leeds Teaching Hospital Trust
Leeds, West Yorkshire, United Kingdom, LS9 7TF